Home / 2021 / April / 09

Daily Archives: April 9, 2021

Philips showcases impact of tele-ultrasound advancing Precision Diagnosis at AIUM virtual event

April 9, 2021

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its participation in the upcoming Annual Integrative Ultrasound Meeting (AIUM) virtual event, April 11-14, hosted by the American Institute of Ultrasound in Medicine. The company will spotlight its latest advanced tele-ultrasound solutions, extending access and consistency of care and expanding capacity of care teams by enabling remote clinician to clinician collaboration.

As telemedicine continues to grow in adoption, especially during the COVID-19 pandemic, the evolution of ultrasound has been revolutionized by the expansion of tele-ultrasound, demonstrating its ability to extend global access to quality care across cardiovascular, general imaging and women’s healthcare, regardless of geographic limitations. Advancements in point-of-care (POC) ultrasound are showing tremendous promise in rural and underserved areas of the world, allowing users of POC – emergency medicine physicians, intensivists, hospitalists, critical care physicians, medical fellows, residents, and more – to perform exams and consult with patients and one another, all via tele-ultrasound technology.

Spotlight on Philips Handheld Ultrasound (Lumify) with Collaboration Live (Reacts)
At the virtual AIUM event, Philips will highlight its advanced tele-ultrasound solutions, allowing remote and secure communication between clinical teams and patients in real-time, making physical distance less of an obstacle. Philips products – including its award-winning Handheld Ultrasound (Lumify) with Collaboration Live (Reacts), the world’s first truly integrated tele-ultrasound solution providing remote access to clinical staff in real-time during exams – will be front and center at the event. Remote guidance and collaboration allows tele-ultrasound users to eliminate time wasted in switching physical locations and to limit exposure to infectious patients, while increasing productivity and improving the patient and staff experience.

“In the era of COVID-19, the use of remote ultrasound guidance and training is more important than ever before. Patients are very sick, and cannot be examined with a stethoscope in order not to spread the virus from patient to patient,” said Yanick Beaulieu, MD, Cardiologist-Intensivist and Medical Officer for Precision Diagnosis at Philips. “Tools that can deliver tele-guidance have become invaluable. When I am working remotely with one of my residents who is with a COVID patient performing an ultrasound exam with Philips Handheld Ultrasound (Lumify) and Collaboration Live (Reacts), I can see everything she is doing and guide her as if I were in the same room. Bringing expertise to where it is needed most is the true benefit of tele-ultrasound.”

“When you work in a vast state like New Mexico, there are many rural areas, with limited access to high quality obstetric medical care,” said Michael S. Ruma, MD, MPH, a maternal-fetal medicine specialist at Perinatal Associates of New Mexico. “We deal with many common fetal illnesses and abnormalities in our practice. Having access to Philips Collaboration Live, lets me provide real-time consultation to both sonographers and patients to help improve outcomes. Telemedicine has become even more critical during the pandemic, because in-person visits have been greatly limited. Since the onset of COVID-19, we’ve done more than 5,500 telemedicine visits, including many via Philips Collaboration Live, allowing us to reach out and touch patients remotely.”

The impact of Philips tele-ultrasound on patient care
Even before the COVID-19 pandemic, healthcare leaders recognized the need for digital transformation across the imaging enterprise. Enabled by increasingly connected informatics platforms, imaging innovations that support extended, virtual, and collaborative care are rapidly responding to these needs.

During the AIUM virtual event, Philips will host a panel session of leading clinicians to discuss how they are “going remote” to connect with colleagues and patients in new and effective ways via tele-ultrasound, in continued efforts to transform patient care.  The session is open to registration for AIUM attendees. Panelists include:

  • Yanick Beaulieu MD, Cardiologist-Intensivist, Medical Officer for Precision Diagnosis, Philips;
  • Michael S. Ruma MD, MPH, FACOG, with Perinatal Associates of New Mexico, USA;
  • Richard G. Barr MD, PhD, FACR, FSRU, FAIUM, with Southwoods Health in Ohio, USA.

Philips Handheld Ultrasound (Lumify) recognized with recent Frost & Sullivan leadership award
Based on its recent analysis of the global market for integrated telehealth solutions in point-of-care ultrasound, research analyst firm Frost & Sullivan has recognized Philips with the 2020 Global Customer Value Leadership award for Lumify and its revolutionary Reacts collaborative platform and expanded tele-ultrasound capabilities. Noted for its unprecedented connection and collaboration capabilities, Lumify was singled out for its cost-efficient, real-time virtual collaboration during ultrasound examinations, which have become increasingly important during the COVID-19 pandemic. More detail on this most recent worldwide accolade for Lumify is available here.

Visit AIUM 2021 for more detail on Philips participation in the virtual event, and visit Philips advanced tele-ultrasound solutions for more information on Philips Collaboration Live and Philips Handheld Ultrasound (Lumify).

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.




          Thursday 08 April 2021


Akwel (FR0000053027, AKW, PEA-eligible), the automotive and HGV equipment and systems manufacturer specialising in fluid management and mechanisms, posted its 2020 annual results.

Consolidated data – in € millions 2020 2019 Var. in %
Revenue 937.2 1,101.2 -14.9%
EBITDA 175.3 130.3 +34.6%
Current operating income 113.7 92.2 +23.4%
Current operating margin 12.1% 8.4% +3.7 pts
Operating income 107.0 88.9 +20.3%
Financial income (1.9) (2.4)
Net result (group share) 85.5 62.7 +36.4%
Net margin 9.1% 5.7% +3.4 pts

Thanks to the upturn in activity during the last four-month period,  the annual fall in turnover was -14.9% and -10.9%, at a constant exchange rate and comparable perimeter.

The EBITDA increased by 34.6%, thanks to the group quickly adapt of its cost structure under crisis conditions, the work focusing on profitability carried out by the teams since 2019 and the levels of operational maturity of the new sites.

The group’s self-financing capacity of €154.4m, the improvement in working capital requirements down by €7.7m, and the management of the investment budgets (€34m) resulted in free cash flow generation of €128.2m. With a positive net cash position of €60.6m, AKWEL enjoys a particularly solid financial situation enabling it to come through this crisis. The payment of a dividend of €0.45 per share will be proposed for the 2020 financial year.

AKWEL is forecasting an increase in activity over the financial year underway but at this stage is not anticipating a level of profitability and cash generation comparable to that seen during the 2020 financial year. The outlook for new mobility solutions – and particularly the development of hydrogen – and increasing demands in the Corporate Social Responsibility field will be key areas on which we will be focusing in 2021. AKWEL will also be in a position to seize external growth opportunities offering the potential to extend its product range beyond combustion engines or to improve its geographical position.

An independent, family-owned group listed on the Euronext Paris Stock Exchange, AKWEL is an automotive and HGV equipment and systems manufacturer specialising in fluid management and mechanisms, offering first-rate industrial and technological expertise in applying and processing materials (plastics, rubber, metal) and mechatronic integration.

Operating in 20 countries across every continent, AKWEL employs almost 11,200 people worldwide.


Nyxoah Reports Full Year 2020 Results

Nyxoah Reports Full Year 2020 Results

Conference call and webcast today at 3pm CET / 9am ET

Mont-Saint-Guibert, Belgium – 9 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the full year ended December 31, 2020.

Olivier Taelman, Chief Executive Officer of Nyxoah, said: “2020 was a year marked by key accomplishments for Nyxoah, with important milestones showing focused execution across business units. Despite the Covid-19 pandemic, the impact on Nyxoah’s activities was limited and our manufacturing facilities remained operational, with sufficient production to meet our needs.”

Key Points

  • Financial
    • 25M€ round onboarding ResMed as new investor
    • 85M€ IPO on Euronext Brussels
  • Clinical
    • BETTER SLEEP study enrolment close of 42 implanted patients M6 data to be expected Q2 2021
    • IDE trial approval by FDA in June 2020, with first US and international implants by end 2020
    • EliSA implants on 15 patients for long term safety & efficacy, trial expected to follow patients over a five-year period
  • Commercial
    • Germany G-BA approving NUB reimbursement at a similar reimbursement level as other neurostimulation-based OSA therapies
    • First revenue generation in Germany
  • Operational
    • No production stop despite COVID
    • Tech transfer to a second independent manufacturing site in Belgium started
  • R&D
    • MRI compatibility full body 1.5T and 3T
    • Next Gen of Genio system with improved features for the implantable and external components

Highlights of 2020

  • In 2020, the Company continued to advance its goal of further expanding its footprint and providing more patients suffering from OSA access to the Genio® solution, thereby addressing a significant current unmet medical need.
  • The German federal joint committee (G-BA) confirmed in March 2020 that the Genio® system is entitled to join the existing NUB for hypoglossal nerve stimulation (“HGNS”) systems at a similar reimbursement level as other neurostimulation-based OSA therapies. As a result, the Company generated its first commercial revenue in 2020, albeit that such revenue was limited due to the NUB-specific negotiation path. As of 2021, the reimbursement will move away from NUB into a DRG system which should allow the Company to fully ramp up its German commercialization strategy.
  • Despite Covid-19 related disruptions, the Company was able to continue producing Genio® devices in sufficient quantities to meet needs.

Clinical development

  • In November 2020, the Company completed enrolments in the BETTER SLEEP trial, conducted in Australia. In total, 42 patients were enrolled in this pre-marketing study, designed to assess the safety and efficacy / performance of the Genio® system for the treatment of OSA in adult patients who either exhibit or do not exhibit a complete concentric collapse (“CCC”) of the soft palate. The study is planned to have a 36-month follow-up and the end of the study is expected by the end of 2023. Six-month follow-up results are expected to be available in the second quarter of 2021.
  • If the primary endpoints of this study are reached, the Company plans to request a therapy indication expansion that would allow the Genio system to be used to treat CCC patients that are currently excluded from HGNS. In the meantime, the discussion with the European notified bodies has been initiated. If the Company obtains marketing authorization for the Genio system in the US, the Company plans to leverage the clinical data from the BETTER SLEEP study to expand the authorized indication to include the treatment of CCC patients in the US.
  • In 2020, enrolment continued, but was slowed down due to Covid-19, in the EliSA trial, the Company’s multicenter post-marketing trial being conducted throughout Europe which is designed to gather long-term safety and clinical data regarding the Genio® system in adult patients suffering from moderate-to-severe OSA. As of 31 December 2020, 15 patients out of the total intended 110 patients were enrolled in the study coming from five different countries (Germany, Switzerland, France, the Netherland, Belgium).
  • In June 2020, the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application for the Company’s DREAM trial. This study aims to confirm the safety and effectiveness of the Genio® system and is designed to support marketing authorization of the Genio® system in the United States. The study will enroll 134 moderate-to-severe OSA patients who failed first line CPAP therapy. Up to 19 US sites in combination with 7 international sites have been selected to participate in the study. By the end of 2020, the first US and international implants took place.

Research and Development

  • Throughout 2020, the Company continued to invest in improving the Genio® system with a goal of developing next generation products with improved features with respect to patient comfort, therapy efficacy, reliability and patient and market acceptance.
  • In 2020, the Company performed the Magnetic Resonance Imaging (“MRI”) compatibility testing of the Genio® system, resulting in CE mark and FDA conditional MR labeling approval in early 2021.

Financial highlights

  • In February 2020, the Company raised €25 million in a private financing round, whereby ResMed Inc. (NYSE:RMD; ASX:RMD), a world-leading digital health company in the OSA field, joined the Company as a new shareholder. All major shareholders at that time participated in this financing round onboarding ResMed Inc.
  • In September 2020, the Company raised €85 million ($100 million) as a result of the initial public offering (“IPO”) of new shares of the Company on Euronext Brussels under the symbol “NYXH”. The IPO resulted in an initial market capitalization of €375 million (taking into account the exercise in full of the over-allotment option in the framework of the IPO).

Subsequent Events

  • After the close of the financial year, the Company signed an exclusive license agreement with Vanderbilt University (Nashville, TN, USA). This agreement allows Nyxoah to develop new neurostimulation technologies for the treatment of sleep disordered breathing conditions based on inventions and patents owned by Vanderbilt University, which could potentially expand Nyxoah’s future pipeline.
  • On February 22, 2021, the Company issued 10,000 shares pursuant to an exercise of subscription rights. Consequently, on the date of this Annual Report, the Company’s registered capital amounts to EUR 3,797,765.64, represented by 22.107.609 shares.

Outlook for 2021

Our business, operational, and clinical outlook for 2021 include the following:

  • Ramp up EU revenue and build a dedicated sales team in Germany
  • Obtain reimbursement in Switzerland
  • BETTER SLEEP trial 6 month results, basis for Complete Concentric Collapse (“CCC”) therapeutic indication expansion
  • Open second independent manufacturing site in Belgium, in addition to existing site in Israel
  • Complete DREAM pivotal trial enrollment

Full Year 2020 Financial Results
Income Statement

For the first time since its inception, the Company began generating revenue as of July 2020. The revenue of KEUR 69 was generated under the existing HGNS NUB coding in Germany. The total cost of goods sold was KEUR 30.

Operating costs increased to KEUR 11,224 in 2020 from KEUR 7,715 in 2019, or a change of KEUR 3,509, due to increases of activities in all departments. The Company is currently conducting three clinical trials to continue gathering clinical data and obtain regulatory approvals. In June 2020 the Company obtained FDA approval to start the DREAM study in the US. In line with its strategy, the Company continues investing in research and development to improve and develop the next generation of the Genio® system and preparing for scaling-up of production capacities.

General and administrative expenses increased by 78% to KEUR 7,522 in 2020 from KEUR 4,226 in 2019. The increase is due to consulting expenses, staff and legal fees to support the Company growth. The increase in consulting and contractors’ fees includes variable compensations of KEUR 1,981 related to a cash-settled share-based payment transaction (2019: KEUR 1,199). The increase of KEUR 159 in legal fees is due to services and not to any ongoing disputes.

Research and development expenses increased by 29% to KEUR 3,066 in 2020 from KEUR 2,375 in 2019, before capitalization of KEUR 2,593 in 2020, due to the increase of development costs of the Genio® system.  Research and development expenses consist of product development, engineering to develop and support our products, testing, consulting services and other costs associated with the next generation of the Genio® system that do not meet the development capitalization criteria. The Company continues to invest in improving the Genio® system to develop next generation products with improved features with respect to patient comfort, therapy efficacy, reliability and patient and market acceptance. These expenses primarily include employee compensation and outsourced development expenses.

Clinical expenses increased by 50% to KEUR 4,316 in 2020 from KEUR 2,881 in 2019, before capitalization of KEUR 3,263 in 2020. The increase in the expenses was mainly due to an increase in staff and consulting to support the completion of the BETTER SLEEP study implantations, continuous recruitment for EliSA study and the launch of the new DREAM IDE study in the US. Clinical expenses consist of clinical studies related to the development of our Genio® system, consulting services and other costs associated with clinical activities. These expenses include employee compensation, clinical trial management and monitoring, payments to clinical investigators, data management and travel expenses for our various clinical trials.

Manufacturing expenses increased by 109% to KEUR 3,802 in 2020 from KEUR 1,812 in 2019, before capitalization of KEUR 3,342 in 2020. The increase in the expenses was mainly due to increases in staff for the production and engineering teams to support capacity and yield improvement, and also due to purchasing raw materials to support increase in the production. Manufacturing and operation expenses consist primarily of acquisition costs of the components of the Genio® system, scrap and inventory obsolescence as well as distribution-related expenses such as logistics and shipping costs.

Quality assurance and regulatory expenses increased by 58% to KEUR 1,474 in 2020 from KEUR 928 in 2019, before capitalization of KEUR 1,247 in 2020. The increase in the expenses was due to staff increases and QA & regulatory activities to support manufacturing scaling up process. Quality assurance and regulatory expenses consist primarily of quality control, quality assurance and regulatory expenses. These expenses include employee compensation, consulting, testing and travel expenses.

Therapy development expenses increased by 107% to KEUR 1,864 in 2020 from KEUR 902 in 2019. The increase in the expenses was due to an increase in staff and consulting to support the commercialization in Europe. Therapy development expenses consist of compensation for personnel, spending related to market access and reimbursement activities. Other therapy development expenses include training physicians, travel expenses, conferences and consulting services.

Balance Sheet

The Company started recognizing the development expenditure as an asset as of March 2019, triggered by obtaining CE mark. Development costs primarily include employee compensation and outsourced development expenses. In 2020, the Company had capitalized developments costs of KEUR 9,874.

Property, plant & equipment shows a total additional net book value of KEUR 391 at balance sheet date consequently to leasehold improvements in the Company’s offices in Belgium and Israel.  Right of use assets shows a total additional increase by KEUR 2,217 due to new leases signed in 2020.

Cash and cash equivalents show a total additional increase of KEUR 86,445. This increase was due to total capital raises of KEUR 103,583, net of transaction costs, in February 2020 and in September 2020 (Initial Public Offering (“IPO”)). Cash from financing activities was offset by cash used in the operating activities of KEUR 7,015 and cash used in the investing activities of KEUR 10,693.

The share capital and the share premium have increased, respectively, by KEUR 1,315 and KEUR 103,268 due to the capital increases in cash in 2020 for a total amount KEUR 103,583, net of transaction costs and capital increase in kind (conversion of loan in shares) of KEUR 1,000.

Lease liabilities shows a total additional increase of KEUR 2,242 due to new lease agreements in Belgium and Israel.

Other non-current and current payables have increased by KEUR 1,303 from KEUR 2,820 to KEUR 4,123 due higher cash-settled share-based payment liability of KEUR 473, higher accrued expenses of KEUR 557 and higher payroll related payables of KEUR 134.

Cash Flow Statement

The net cash burn rate for 2020 is a net cash inflow amounting to KEUR 86,445 compared to a net cash outflow of KEUR 10,950 for 2019.

The cash outflow resulting from operating activities amounted to KEUR 7,015 in 2020 compared to KEUR 5,965 in 2019. An increase of cash outflow of KEUR 1,050 due to KEUR 3,768 higher losses mainly from increased general and administrative expenses and therapy development expenses and higher interest and tax paid, net of KEUR 166, offset by KEUR 2,421 higher non-operating cash adjustments (KEUR 2,202 higher share-based payment expense) and a positive variation in the working capital of KEUR 463.

Cash flow from investing activities represented a net cash outflow of KEUR 10,693 for 2020. An increase of KEUR 4,898 compared to 2019 mainly explained by higher capitalization of development expenses in 2020.

The increase in cash inflow from financing activities is primarily due to the IPO completed in September 2020 and the proceeds from the February 2020 capital raise.

Financial Information

The consolidated financial statements have been prepared in accordance with IFRS as adopted by the EU. The financial information included in this press release is an extract of the full IFRS consolidated financial statements, which will be published on 9 April 2021. The statutory auditor, EY Bedrijfsrevisoren /Réviseurs d’Entreprises SRL, represented by Carlo-Sébastien D’Addario, has issued an unqualified audit opinion with emphasis of matter paragraph relating to a restatement for the year 2019 and the balance at 1 January 2019 to reflect the adjustments relating to a share based compensation accrual.

2021 Financial & Events Calendar

  • 09 April 2021                               Full Year 2020 Financial and Operating Results & Annual Report
  • 09 June 2021                              Annual Shareholders’ Meeting
  • 31 August 2021                          Interim Financial Report H1, 2021
  • 14-15 September 2021           Baird 2021 Global Healthcare Conference (virtual)

Conference Call & Webcast
Nyxoah will host a conference call with live webcast today at 3pm CET/9am ET. The webcast may be accessed on the Events page of the company’s website or by clicking here. A replay of the webcast will be available on the Nyxoah website.

For further information, please contact:
Fabian Suarez, Chief Financial Officer
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal
law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations and projections concerning future events such as the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other

factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such
forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Consolidated Income Statement

  For the year ended 31 December
 (in EUR 000)  2020 2019
Restated *
Revenue 69
Cost of goods sold (30)
Gross Profit 39
General and administrative expenses (7,522) (4,226)
Research and development expenses (473) (630)
Clinical expenses (1,053) (848)
Manufacturing expenses (460) (489)
Quality assurance and regulatory expenses (227) (227)
Patents Fees & Related (123) (267)
Therapy Development expenses (1,864) (902)
Other operating income/ (expenses) 459 (126)
Operating loss for the period (11,224) (7,715)
Financial income 62 71
Financial expense (990) (740)
Loss for the period before taxes (12,152) (8,384)
Taxes (93) (70)
Loss for the period (12,245) (8,454)
Loss attributable to equity holders1 (12,245) (8,454)
Other comprehensive (loss) / income
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences (58) 168
Total comprehensive loss for the year, net of tax (12,303) (8,286)
Loss attributable to equity holders1 (12,303) (8,286)
Basic Earnings Per Share (in EUR) (0.677) (0.568)
Diluted Earnings Per Share (in EUR) (0.677) (0.568)


Consolidated Statement of Financial Position

As of and for the year ended 31 December
 (in EUR 000)  2020 2019
Non-current assets
Property, plant and equipment 713 322
Intangible assets 15,853 5,734
Right of use assets 3,283 1,066
Deferred tax asset 32 21
Other long-term receivables 91 78
19,972 7,221
Current assets
Inventory 55
Trade receivables 60
Other receivables 1,644 2,048
Other current assets 109 11
Cash and cash equivalents 92,300 5,855
94,108 7,974
Total assets 114,080 15,195
Capital and reserves
Capital 3,796 2,481
Share premium 150,936 47,668
Share based payment reserve 2,650 420
Currency translation reserve 149 207
Retained Earnings (60,341) (48,415)
Total equity attributable to shareholders 97,190 2,361
Non-current liabilities
Financial debt 7,607 7,146
Lease liability 2,844 735
Pension Liability 37 30
Other payables 547
10,488 8,458
Current liabilities
Financial debt 616 378
Lease liability 473 340
Trade payables 1,190 1,385
Other payables 4,123 2,273
6,402 4,376
Total liabilities 16,890 12,834
Total equity and liabilities 114,080 15,195


* The year 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note ‎5.2.3

Consolidated Statement of Cash Flows

For the year ended 31 December
 (in EUR 000)  2020 2019
Restated *
Loss before tax for the year (12,152) (8,384)
Adjustments for:
Finance income (62) (71)
Finance expenses 990 740
Depreciation and impairment of property, plant
and equipment and right-of-use assets
620 433
Share-based payment transaction expense 2,549 346
Pension-related expenses 7 30
Other non-cash items2 (134) 70
Cash generated before changes in working capital (8,182) (6,836)
Changes in working capital:
Increase in Inventory (55)
Decrease/(Increase) in Trade and other receivables 365 (1,385)
     Increase in Trade and other payables 1,109 2,342
Cash generated from changes in operations (6,763) (5,879)
Interests received 3 8
Interests paid (151) (33)
Income tax paid (104) (61)
Net cash used in operating activities (7,015) (5,965)
Purchases of property, plant and equipment (562) (51)
Capitalization of intangible assets (10,118) (5,734)
 Increase of long-term deposits (13) (10)
Net cash used in investing activities (10,693) (5,795)
Payment of principal portion of lease liabilities (479) (341)
Repayment of other loan (63) (82)
Recoverable cash advance received 190 1,196
Repayment of recoverable cash advance (55) (40)
Proceeds from convertible loan 1,000
Proceeds from issuance of shares, net of transaction costs 103,583
Net cash generated/(used) from financing activities 104,176 733
Movement in cash and cash equivalents 86,468 (11,027)
Effect of exchange rates on cash and cash equivalents (23) 77
Cash and cash equivalents at 1 January 5,855 16,805
Cash and cash equivalents at 31 December 92,300 5,855

Consolidated Statement of Changes in Equity

Attributable to owners of the parent
  (in EUR 000)  Notes Capital Share premium Share based payment reserve Currency translation reserve Retained earnings Total
Balance at 1 January 2019* restated      2,481 47,668 80 39 (39,967) 10,301
Loss for the year (8,454) (8,454)
Other comprehensive income for the year 168 168
Total comprehensive income/(loss) for the year 168 (8,454) (8,286)
Equity-settled share-based payment plan 340 6 346
Total transactions with owners of the Company recognized directly in equity 340 6 346
Balance at 31 December 2019 restated * 2,481 47,668 420 207 (48,415) 2,361
Balance at 1 January 2020 restated * 2,481 47,668 420 207 (48,415) 2,361
Loss for the year (12,245) (12,245)
Other comprehensive loss for the year (58) (58)
Total comprehensive loss for the year (58) (12,245) (12,303)
Equity-settled share-based payment plan 2,230 319 2,549
Issuance of shares for cash 1,304 108,857 110,161
Issuance of shares in kind 11 989 1,000
Transaction cost (6,578) (6,578)
Total transactions with owners of the Company recognized directly in equity 1,315 103,268 2,230 319 107,132
Balance at 31 December 2020 3,796 150,936 2,650 149 (60,341) 97,190


* The year 2019 and the balance at 1 January 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note ‎5.2.3


1 For the years ending 31 December 2020 and 2019, the loss is fully attributable to equity holders of the Company as the Company does not have any non-controlling interests.
* The year 2019 has been restated to reflect the adjustments as explained in Note ‎5.2.3


2 The other non-cash items include (i) the impact of the initial measurement and re-measurement of recoverable cash advances (see our 2020 Annual Report notes ‎5.14  ,‎5.24 and (ii) the evolution of the deferred tax assets.
* The year 2019 has been restated to reflect the adjustments as explained in our 2020 Annual Report Note ‎5.2.3


Yadim needs RM50 million a year for dakwah activities

Yayasan Dakwah Islamiah Malaysia (Yadim) needs RM50 million a year to fund its dakwah (missionary) activities in various fields, said its president Nasrudin Hassan.

He said the average annual contribution received by the foundation was only around RM20 million.

“We need more funds to move more actively because the target of our dakwah involves various segments such as people in Sabah, Sarawak, Orang Asli and asnaf (zakat recipients) as well as victims of natural disasters.

“Besides dakwah through lectures, street dakwah and such, we also need allocation for programmes to train new preachers and distribution of brochures about Islam to the people,” he said after the signing of a joint-venture agreement between Yadim and MobilityOne Sdn Bhd here today.

The five-year agreement is for the development and implementation of fintech (financial technology) services for the foundation’s infak (contribution) programmes.

Meanwhile, MobilityOne chief executive officer Datuk Hussian A Rahman said the collaboration will facilitate donors in using various digital payment channels to contribute to Yadim, among them MobilityOne e-pos terminal, Yadim official portal and mobile applications.

“We expect that three months from now, the infak payment system for Yadim, developed by our company, will be fully operational,” he said.

Minister in the Prime Minister’s Department (Religious Affairs) Datuk Seri Dr Zulkifli Mohamad Al-Bakri, who witnessed the signing of the agreement, expressed hope that the collaboration will make Yadim stronger and better in delivering dakwah.

Source: BERNAMA News Agency

Confirm caccination appointment within 48 hours of notification or risk cancellation – CITF

COVID-19 vaccine recipients in phase two of the National COVID-19 Immunisation Programme are reminded to confirm their vaccination appointment within 48 hours of receiving their details or risk having it cancelled, and rescheduled to a later date.

The COVID-19 Immunisation Task Force (CITF) in a statement today said the slots for those who failed to respond to the appointment notification would then be given to others, as this would ensure that vaccination process could be carried out smoothly.

“If they (recipients) confirm to be present for the vaccination appointment, a reminder will be sent three days, as well as a day prior to the date,” it said, adding that the notification for the appointment and the reminders would be sent both via the MySejahtera application and the Short Message Service (SMS).

For those who have not registered through MySejahtera, the appointment details will be sent via SMS, and the confirmation can be done by replying ‘YES’ or ‘NO’ to the message.

The second phase of the national immunisation programme is set to begin on April 19, targeting at-risk groups such as the elderly, individuals with comorbidities and persons with disabilities.

The details of the appointments were sent to recipients beginning Monday (April 5).

Members of the public with any queries regarding their appointment may contact the hotline at 1800-888-828.

Source: BERNAMA News Agency

MAFI committed to rejuvenate agriculture sector

The Ministry of Agriculture and Food Industries (MAFI) will continue to rejuvenate the agriculture sector by increasing the involvement of the younger generation in its programmes.

Deputy Minister II Datuk Che Abdullah Mat Nawi said the government had succeeded in increasing the involvement of young people in 2020 when a total of 1,149 people received grants amounting to RM21.7 million compared to 750 people in 2019 and 785 people in 2018.

For the Young Agropreneur Grant (GAM) programme, he said the ministry had allocated RM15 million for 750 young entrepreneurs this year.

“Business courses are always being carried out to provide exposure to agriculture and agro-food entrepreneurs, as well as qualify them to received grants of up to RM20,000.

“The involvement of more young people can help the ministry to increase production for the agriculture sector because these people are skilled in using modern technology,” he told reporters after opening the Young Agropreneur Business Plan Course here today.

He said the scope of the programme was to provide grant assistance in the form of goods up to RM20,000 for new projects, capital assistance through the TEKUN Nasional Special Financing Package up to RM50,000 and the Agro-YES Financing Package (up to RM500,000) for expansion projects.

At the event, Che Abdullah also presented GAM mock cheques worth a total of RM960,000 to 51 recipients in Penang.

Source: BERNAMA News Agency

Road safety campaign to check high fatal accident rate among p-hailing riders

A road safety campaign has been launched to curb accidents involving p-hailing riders, who accounted for two-thirds of the 2,576 motorcyclists killed in the nine months of the Movement Control Order (MCO) last year.

Quoting statistics from the Royal Malaysia Police, Transport Minister Datuk Seri Dr Wee Ka Siong said it was sad that these breadwinners had lost their lives in road accidents.

“While children lost their fathers or mothers, there were also social and economic effects on the dependents,” he said, adding that an estimated 100,000 individuals are involved in p-hailing service in the country.

Wee said this today when launching the road safety campaign themed ‘Careful Ride, Safe Delivery’, a joint initiative by the government and service providers to increase awareness of road users and reduce accident rates.

He said studies by the Malaysian Institute of Road Safety Research (Miros) based on closed-circuit television (CCTV) recordings showed that 70 per cent of p-hailing riders adopted risky practices at peak hours, including stopping in yellow boxes, jumping the red light and using mobile phones while riding.

During the six-month campaign, road safety messages will be disseminated via pop-up apps and training sessions on safe riding and activities on monitoring of road conduct will be conducted.

Reminders will be also be issued directly to all motorcyclists at traffic light intersections equipped with CCTV cameras and loud speakers.

Source: BERNAMA News Agency